Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 17;15(1):3315.
doi: 10.1038/s41467-024-47720-8.

Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection

Affiliations

Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection

Chansavath Phetsouphanh et al. Nat Commun. .

Abstract

This study investigates the humoral and cellular immune responses and health-related quality of life measures in individuals with mild to moderate long COVID (LC) compared to age and gender matched recovered COVID-19 controls (MC) over 24 months. LC participants show elevated nucleocapsid IgG levels at 3 months, and higher neutralizing capacity up to 8 months post-infection. Increased spike-specific and nucleocapsid-specific CD4+ T cells, PD-1, and TIM-3 expression on CD4+ and CD8+ T cells were observed at 3 and 8 months, but these differences do not persist at 24 months. Some LC participants had detectable IFN-γ and IFN-β, that was attributed to reinfection and antigen re-exposure. Single-cell RNA sequencing at the 24 month timepoint shows similar immune cell proportions and reconstitution of naïve T and B cell subsets in LC and MC. No significant differences in exhaustion scores or antigen-specific T cell clones are observed. These findings suggest resolution of immune activation in LC and return to comparable immune responses between LC and MC over time. Improvement in self-reported health-related quality of life at 24 months was also evident in the majority of LC (62%). PTX3, CRP levels and platelet count are associated with improvements in health-related quality of life.

PubMed Disclaimer

Conflict of interest statement

G.J.D. received grants from Gilead, Abbvie, Merck and Bristol-Myers Squibb, personal fees from Gilead, Abbvie and Merck, and nonfinancial support from Gilead, Abbvie and Merck, all outside the scope of the submitted work. B.J.B. received grants from St Vincent’s Clinic during the conduct of the study; and consults for AbbVie, Janssen and Viiv, and grants from Biogen, all outside the scope of the submitted work. All other authors declare that there are no competing interests.

Figures

Fig. 1
Fig. 1. Humoral response in participants with long COVID following SARS-CoV-2 infection.
A Anti-spike IgG levels were elevated in LC at earlier timepoints. B Higher anti-nucleocapsid were significantly higher at 3-months in LC. C Neutralization tired remained higher in LC up to 8-months post-infection. There was no difference following vaccination at 12- or 24-months. D Similar frequencies of bulk CD19 + B-cells between the two groups. E Representative dot plots showing spike tetramer binding from memory (IgD-) B cells. Increased frequencies of spike-specific B cells evident following vaccination. F Representative dot plots showing nucleocapsid tetramer binding from memory (IgD-) B cells. Data shown as medians with interquartile ranges. LC= Long COVID, MC= matched controls, M= months. Mann–Whitney U test (two-sided) was used for un-paired analysis, p < 0.05 (*) were considered significant. Data points represent n = 31 biologically independent samples per group. Source data are provided as a Source Data file.
Fig. 2
Fig. 2. T cells responses and Inhibitory marker expression in participants with long COVID.
A, B Spike-specific and nucleocapsid-specific CD4+T cell responses were higher in LC at 3- and 8-months. No difference at 24-months. C, D Sustained spike-specific and nucleocapsid-specific CD8 + T cell responses across all 3 timepoints. E No difference in PD-1 expression on CD4+ T cells. F Elevated PD-1 expression on CD8+ T cells at 3- and 8-months. G, H Increased TIM-3 expression on CD4 and CD8 T cells at earlier timepoints. Data shown as medians with interquartile ranges. LC= Long COVID, MC= matched controls. Mann–Whitney U test (two-sided) was used for un-paired analysis, p < 0.05 (*), < 0.01 (**) were considered significant. Data points represent n = 31 biologically independent samples per group. Source data are provided as a Source Data file.
Fig. 3
Fig. 3. Reduction of immune activation at 24-months.
A Significantly elevated IFN-γ and IFN-β in LC at 24-months. B Higher frequencies of activated monocytes at 3- and 8-month, but not 24-months. C Lower percentages of activated myeloid dendritic cells (mDC) at 24-months. D Higher percentages of activated plasmacytoid dendritic cells (pDC) at 3- and 8-month that decreased 24-months. Data shown as medians with interquartile ranges. LC Long COVID, MC matched controls. Mann–Whitney U test (two-sided) was used for un-paired analysis, p < 0.05 (*), < 0.01 (**) were considered significant. Data points represent n = 31 biologically independent samples per group. Source data are provided as a Source Data file.
Fig. 4
Fig. 4. Reconstitution of immune cell subsets at 24-months.
A Longitudinal plot showing changes in cell subset proportions overtime (3-, 8- and 24-months) in MC (left) and LC (right) (B) UMAP showing cellular composition single-cell RNAseq data; all (combined cells [45,988 cells]) then separated into LC (n = 10) and MC (n = 10) at 24-months. C Composition of cell subset frequencies between LC and MC with p values and false discovery rate (FDR). D UMAP assessing only naïve B and T cell subsets, with no clear difference between LC or MC. E Box and whiskers graph (median with IQR) showing interferon response scores (IRS) in innate cell subsets. Elevated IRS in CD14+ monocytes. F Exhaustion score in T cell subsets. Dots represent individual cells (outliers) for each subset with weighted scores (median with IQR). LC Long COVID, MC matched controls. Data shown as mean scores. p < 0.05 (*), < 0.0001(****) were considered significant. Data represent n = 10 biologically independent samples per group. Source data are provided as a Source Data file.
Fig. 5
Fig. 5. Changes in health-related quality of life by EQ-5D-5L index score.
EQ-5D-5L index score at 4-month visit are ordered ascending on the x-axis for Matched Control (A) and Long COVID (B) participants. Vertical lines connect the participants’ initial EQ-5D-5L score (4-month) and the last available EQ-5D-5L score (12- or 24-month). Crosses = EQ-5D-5L index score at 4-month visit, Triangle symbol = EQ-5D-5L index score at 12-month visit, Circle symbol = EQ-5D-5L index score at 24-month visit, Closed symbol = no COVID-19 reinfection during follow-up, Open symbol = COVID-19 reinfection during follow-up. C Median (dark dashed line) and participant (pale solid line) trajectories of EQ−5D-5L index score over study follow-up. D Participant-reported functional status at 24-months post-infection, related to full recovery from COVID, return to COVID-19 work, return to usual activities, and return to exercise level. LC Long COVID, MC matched controls.
Fig. 6
Fig. 6. Blood parameters associated with improvement in health-related quality of life at 24-months.
A Representative bar graph of log-linear model, showing frequency of features highly associated with recovery. B Table summarizing accuracy and F1 score for top 2 and top 3 most highly associated features. CI = 95% confidence interval. C Left-panel: 3-dimensional scatter plot of recovered vs unrecovered participant with concentration values of 3 markers (PTX3, CRP and platelets). Right-panel: 2D projections of PTX3 vs platelets (upper) and PTX3 vs. CRP (lower) with line representing the decision boundary. Recovered refers to improvement in health-related quality of life, unrecovered= no improvements, MC matched controls. Source data are provided as a Source Data file.

References

    1. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259–264. doi: 10.1038/s41586-021-03553-9. - DOI - PubMed
    1. Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601–615. doi: 10.1038/s41591-021-01283-z. - DOI - PMC - PubMed
    1. Baig AM. Deleterious outcomes in long-hauler COVID-19: the effects of SARS-CoV-2 on the CNS in chronic COVID syndrome. ACS Chem. Neurosci. 2020;11:4017–4020. doi: 10.1021/acschemneuro.0c00725. - DOI - PubMed
    1. Baig AM. Chronic COVID syndrome: need for an appropriate medical terminology for long-COVID and COVID long-haulers. J. Med. Virol. 2021;93:2555–2556. doi: 10.1002/jmv.26624. - DOI - PubMed
    1. Sykes DL, et al. Post-COVID-19 symptom burden: what is Long-COVID and how should we manage it? Lung. 2021;199:113–119. doi: 10.1007/s00408-021-00423-z. - DOI - PMC - PubMed

Substances